35804462|t|Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions.
35804462|a|BACKGROUND: Alzheimer's disease (AD) pathology is associated with complex interactions among multiple factors, involving an intertwined network of various signaling pathways. The polypharmacological approach is an emerging therapeutic strategy that has been proposed to overcome the multifactorial nature of AD by targeting multiple pathophysiological factors including amyloid-beta (Abeta) and phosphorylated tau. We evaluated a blood-brain barrier penetrating phosphodiesterase 5 (PDE5) inhibitor, mirodenafil (5-ethyl-2-7-n-propyl-3,5-dihydrro-4H-pyrrolo[3,2-d]pyrimidin-4-one), for its therapeutic effects on AD with polypharmacological properties. METHODS: To evaluate the potential of mirodenafil as a disease-modifying AD agent, mirodenafil was administered to test its effects on the cognitive behaviors of the APP-C105 AD mouse model using the Morris water maze and passive avoidance tests. To investigate the mechanisms of action that underlie the beneficial disease-modifying effects of mirodenafil, human neuroblastoma SH-SY5Y cells and mouse hippocampal HT-22 cells were used to show mirodenafil-induced alterations associated with the cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein kinase (PKG)/cAMP-responsive element-binding protein (CREB) pathway, apoptotic cell death, tau phosphorylation, amyloidogenesis, the autophagy-lysosome pathway, glucocorticoid receptor (GR) transcriptional activity, and the Wnt/beta-catenin signaling. RESULTS: Here, mirodenafil is demonstrated to improve cognitive behavior in the APP-C105 mouse model. Mirodenafil not only reduced the Abeta and phosphorylated tau burdens in vivo, but also ameliorated AD pathology induced by Abeta through the modulation of the cGMP/PKG/CREB signaling pathway, glycogen synthase kinase 3beta (GSK-3beta) activity, GR transcriptional activity, and the Wnt/beta-catenin signaling in neuronal cells. Interestingly, homodimerization and nuclear localization of GR were inhibited by mirodenafil, but not by other PDE5 inhibitors. In addition, only mirodenafil reduced the expression levels of the Wnt antagonist Dickkopf-1 (Dkk-1), thus activating the Wnt/beta-catenin signaling. CONCLUSIONS: These findings strongly suggest that the PDE5 inhibitor mirodenafil shows promise as a potential polypharmacological drug candidate for AD treatment, acting on multiple key signaling pathways involved in amyloid deposition, phosphorylated tau burden, the cGMP/PKG/CREB pathway, GSK-3beta kinase activity, GR signaling, and the Wnt/beta-catenin signaling. Mirodenafil administration to the APP-C105 AD mouse model also improved cognitive behavior, demonstrating the potential of mirodenafil as a polypharmacological AD therapeutic agent.
35804462	0	19	Phosphodiesterase 5	Gene	242202
35804462	30	41	mirodenafil	Chemical	MESH:C528396
35804462	54	63	Alzheimer	Disease	MESH:D000544
35804462	127	146	Alzheimer's disease	Disease	MESH:D000544
35804462	148	150	AD	Disease	MESH:D000544
35804462	423	425	AD	Disease	MESH:D000544
35804462	499	504	Abeta	Gene	11820
35804462	577	596	phosphodiesterase 5	Gene	242202
35804462	598	602	PDE5	Gene	242202
35804462	615	626	mirodenafil	Chemical	MESH:C528396
35804462	628	694	5-ethyl-2-7-n-propyl-3,5-dihydrro-4H-pyrrolo[3,2-d]pyrimidin-4-one	Chemical	-
35804462	728	730	AD	Disease	MESH:D000544
35804462	806	817	mirodenafil	Chemical	MESH:C528396
35804462	841	843	AD	Disease	MESH:D000544
35804462	851	862	mirodenafil	Chemical	MESH:C528396
35804462	943	945	AD	Disease	MESH:D000544
35804462	946	951	mouse	Species	10090
35804462	1113	1124	mirodenafil	Chemical	MESH:C528396
35804462	1126	1131	human	Species	9606
35804462	1132	1145	neuroblastoma	Disease	MESH:D009447
35804462	1146	1153	SH-SY5Y	CellLine	CVCL:0019
35804462	1164	1169	mouse	Species	10090
35804462	1182	1187	HT-22	CellLine	CVCL:0321
35804462	1212	1223	mirodenafil	Chemical	MESH:C528396
35804462	1264	1294	cyclic guanosine monophosphate	Chemical	MESH:D006152
35804462	1296	1300	cGMP	Chemical	MESH:D006152
35804462	1333	1336	PKG	Gene	5592
35804462	1379	1383	CREB	Gene	1385
35804462	1437	1452	amyloidogenesis	Disease	
35804462	1486	1509	glucocorticoid receptor	Gene	14815
35804462	1511	1513	GR	Gene	14815
35804462	1553	1565	beta-catenin	Gene	12387
35804462	1592	1603	mirodenafil	Chemical	MESH:C528396
35804462	1666	1671	mouse	Species	10090
35804462	1679	1690	Mirodenafil	Chemical	MESH:C528396
35804462	1712	1717	Abeta	Gene	11820
35804462	1779	1781	AD	Disease	MESH:D000544
35804462	1803	1808	Abeta	Gene	11820
35804462	1839	1843	cGMP	Chemical	MESH:D006152
35804462	1844	1847	PKG	Gene	5592
35804462	1848	1852	CREB	Gene	1385
35804462	1872	1902	glycogen synthase kinase 3beta	Gene	56637
35804462	1904	1913	GSK-3beta	Gene	56637
35804462	1925	1927	GR	Gene	14815
35804462	1966	1978	beta-catenin	Gene	12387
35804462	2068	2070	GR	Gene	14815
35804462	2089	2100	mirodenafil	Chemical	MESH:C528396
35804462	2119	2123	PDE5	Gene	242202
35804462	2154	2165	mirodenafil	Chemical	MESH:C528396
35804462	2218	2228	Dickkopf-1	Gene	13380
35804462	2230	2235	Dkk-1	Gene	13380
35804462	2262	2274	beta-catenin	Gene	12387
35804462	2340	2344	PDE5	Gene	242202
35804462	2355	2366	mirodenafil	Chemical	MESH:C528396
35804462	2435	2437	AD	Disease	MESH:D000544
35804462	2503	2521	amyloid deposition	Disease	MESH:D058225
35804462	2554	2558	cGMP	Chemical	MESH:D006152
35804462	2559	2562	PKG	Gene	5592
35804462	2563	2567	CREB	Gene	12912
35804462	2604	2606	GR	Gene	14815
35804462	2630	2642	beta-catenin	Gene	12387
35804462	2654	2665	Mirodenafil	Chemical	MESH:C528396
35804462	2697	2699	AD	Disease	MESH:D000544
35804462	2700	2705	mouse	Species	10090
35804462	2777	2788	mirodenafil	Chemical	MESH:C528396
35804462	2814	2816	AD	Disease	MESH:D000544
35804462	Association	MESH:C528396	14815
35804462	Negative_Correlation	MESH:C528396	242202
35804462	Association	MESH:D000544	5592
35804462	Association	MESH:C528396	12387
35804462	Negative_Correlation	MESH:C528396	MESH:D000544
35804462	Association	MESH:D000544	56637
35804462	Association	MESH:C528396	12912
35804462	Association	MESH:C528396	MESH:D006152
35804462	Association	MESH:C528396	56637
35804462	Association	MESH:C528396	1385
35804462	Association	MESH:C528396	5592
35804462	Association	MESH:D006152	5592
35804462	Association	MESH:D058225	12912
35804462	Association	MESH:D006152	MESH:D000544
35804462	Negative_Correlation	MESH:C528396	MESH:D009447
35804462	Association	MESH:C528396	13380
35804462	Negative_Correlation	MESH:C528396	11820
35804462	Association	MESH:D000544	242202
35804462	Positive_Correlation	MESH:D000544	11820
35804462	Association	MESH:D006152	1385
35804462	Association	MESH:D000544	1385

